Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009
Date:8/27/2009

LEUVEN, Belgium, August 27 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its half year results for the six month period ending 30 June, 2009.

During 2009, ThromboGenics has continued to focus on the activities which are key to its aim of becoming a profitable, integrated company focused on cutting edge ophthalmic medicines. Central to this plan is the Company's lead product, microplasmin, which is in Phase III trials for the treatment of back of the eye disease. Patient recruitment in this Phase III program is running smoothly and the Company expects to report the first results from these studies by mid 2010.

The clinical development of the Company's unique long-acting anticoagulant TB-402, which is in Phase II trials for the prevention of deep vein thrombosis (DVT) following orthopaedic surgery, has progressed more rapidly than originally expected.

Patrik De Haes, CEO of ThromboGenics, said:

"ThromboGenics has seen most of its key programs make significant progress during the course of 2009. We are very happy with the speed of patient recruitment in the microplasmin Phase III program. Microplasmin is central to our aim of building a strong, profitable and integrated company centered on cutting edge ophthalmic medicines. Given our increasing confidence in the clinical merits of microplasmin we are now starting to develop our commercialization plans for this novel product. We are also very encouraged by the progress of the Phase II program for TB-402, as recruitment is ahead of schedule. This clinical study has reinforced our view that we have an attractive out-licensing opportunity for companies keen to enhance their position in the anti-coagulant therapy market. Our partnership with
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... -- Investor-Edge has initiated coverage on ... GENE ), Agilent Technologies Inc. (NYSE: A ... ), Sequenom Inc. (NASDAQ: SQNM ), and ... report on Genetic Technologies can be accessed at ... the NASDAQ Composite ended at 4,941.42, down 1.64%, ...
(Date:5/1/2015)... SPRING, Md. and RESEARCH TRIANGLE PARK, ... (NASDAQ: UTHR ) announced today that Roger Jeffs ... will provide an overview and update on the company,s business ... Conference in Boston, Massachusetts . ... at 3:30 PM Eastern Time, and can be accessed via ...
(Date:4/30/2015)... 2015   Tamir Biotechnology , a leading developer ... its Ebola antiviral therapy program. Clinical ... currently being evaluated and considered by a number of ... During the first quarter of 2015, the company participated ... The Evaluation of Potential Treatments and Vaccines For Ebola ...
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer and ... production capability to serve biotechnology pharmaceutical clients. A ... continues to drive Nitto Avecia to enhance synthesis ... , In Fall 2014, Nitto Avecia first ... its Milford, MA facility, which is recognized as ...
Breaking Biology Technology:Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2
... any tissue with the Big Blue transgenic,rodent ... Barry W. Glickman ,Centre for Environmental Health, University of ... transgenic rodent mutation,assay,* which carries the ... vector, it is easy to study mutations in male,and ...
... and efficient PCR cloning with pcmv-script PCR cloning kit ... Tim Sanchez Quinn,Lu ,Stratagene Cloning Systems, Inc. , ... cloning,strategy by introducing a new vector for ... The pcmv-script PCR,cloning kit ...
... reagent is effective with a wide variety ... ,Genetic Applications LLC , LipoTAXI ... delivery of foreign DNA into mammalian,cells. In this study, ... conditions for transfecting a reporter plasmid in three common ...
Cached Biology Technology:Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer 2Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer 3Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer 4Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer 5Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer 6Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer 7Mammalian Expression Vector for Efficient Cloning of PCR Fragments 2Mammalian Expression Vector for Efficient Cloning of PCR Fragments 3Mammalian Expression Vector for Efficient Cloning of PCR Fragments 4A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7,Cell Lines 2A Comparison Study of Lipid Tranfection Reagents in A549, NIH 3T3 and COS-7,Cell Lines 3
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
(Date:3/23/2015)... ANGELES , March 23, 2015  In the ... Federal fraud case conviction losses. This figure accounts for ... which, according to The Nilson Report, exceeds $11 billion ... investigative tool after a crime has occurred. Investor ... and polygraph expert Joe Paolella partnered to ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... French . Toronto (June 5, 2009) ... to announce another measure to address the H1N1 flu virus. ... network focused on pandemic vaccine evaluation. The network will strengthen ... pandemic influenza vaccine and vaccination programs. The network was ...
... may shape the human genome much more slowly than ... within and among continents, the expansions and contractions of ... heavily influenced the distribution of genetic variations in populations ... from the Howard Hughes Medical Institute, the University of ...
... EAST LANSING, Mich. A pair of Michigan ... $400,000 for their cardiovascular research projects as part of ... The money, from the National Institutes of Health ... to preserve and create jobs in Michigan while also ...
Cached Biology News:Government of Canada announces funding for research on the H1N1 flu virus 2Geography and history shape genetic differences in humans 2MSU researchers receive $400,000 in first wave of stimulus funding 2
Porcine Serum US Origin 6 Months or Older...
SEQUENASE PCR PRODUCT PRE-SEQU, 1 EA. Category: SEQUENASE....
... off the clot from fasted Cynomolgus monkeys of mixed ... Anticoagulants: N-02: Citrate N-04: ... Potassium Oxalate N-10: EDTA (Na) N-03: ... CPD N-09: K3EDTA N-11: Heparin ...
adult...
Biology Products: